IPAT study: “Impact of Pre-existing invasive Aspergillosis on allogeneic stem cell Transplantation”
In patients with pre-existing invasive aspergillosis allo-HSCT is feasible without progression of fungal infection. However, the influence of invasive pulmonary aspergillosis (IA) on transplant related complications and on long term survival has not been investigated in a larger patient cohort under current conditions. To be able to more precisely investigate the impact of IA on allo-HSCT, a non-interventional prospective study is needed.
- First allo-HSCT
- Diagnosed with acute leukaemia (AL) or MDS
- Both adults and paediatrics
- with and without such infection
The recruitment period closes in October 2020. We have already reached 75% of our inclusion target and would like to ask you to please help us bring this study to a success!
Prospective study on the incidence and outcome of HHV-6 encephalitis in patients who undergo allogeneic haploidentical HSCT
HHV-6 infection is a quite common complication that is increasingly recognized among allogeneic HSCT patients, 30% being the risk of reactivation in high-risk patients (deeply T-depleted HSCT). We recently published high incidence of HHV-6 encephalitis in paediatric patients receiving manipulated haploidentical transplantation (Perruccio et al, BBMT 2018), correlating HHV-6 infection to graft-composition. Moreover, we suggested HHV-6 morbidity other than CNS. With this study we would like to confirm these data and reach more information on the impact of HHV-6 infection on OS and EFS in this transplant setting.
Centre criteria: routine performing of haploidentical transplantation of any type and manipulation.
- Any age
- Diagnosis of AL, MDS or Lymphoma
- Receiving a HAPLO transplant
- with and without HHV6 infection
The recruitment period will closed in June 2020.
Real life management of antibiotic therapy in HSCT
Antimicrobial resistance (AMR) is an increasing problem worldwide and is known to affect also HSCT recipients, with consequent high morbidity and mortality in case of multidrug resistant (MDR) inflections due to Gram-negative bacteria. With reporting the management of antibiotic used in HSCT recipients, we aim to gain more insight in the extent and type of de-escalation approaches used every day in different centres.
All patients admitted to HSCT center after the 8.00 am on the day of the study who are currently neutropenic (< 500 PMN) or were neutropenic for at least 3 days during the previous 14 days.
Short description of the study:
A cross sectional point prevalence study, performed over 2 non consecutive days (1 month apart) which collects data on the use of antibiotics in patients being admitted to HSCT ward on the study days.
The inclusion period:
- One day between 7th and 20st of January 2020 (the choice of a single day is made by the investigator from the centre)
- One day between 4th and 17nd of March 2020
If you are interested in participation, please contact Nina Knelange at email@example.com